Diversified Consumer Services
Company Overview of Stanford University
Stanford University is an educational and research institution that provides academic programs in sciences and interdisciplinary areas. The university offers graduate, undergraduate, executive, professional, continuing, and K-12 education. It focuses on areas such as earth sciences, engineering, humanities and sciences, business, education, law, and medicine. The university also provides research facilities that include Center for Advanced Study in the Behavioral Sciences, National Bureau of Economic Research, Stanford Linear Accelerator Center, Woods Institute for the Environment, Freeman Spogli Institute for International Studies, and Stanford Institute for Creativity and the Arts. Stanfor...
450 Serra Mall
Stanford, CA 94305-2004
Founded in 1885
Key Executives for Stanford University
President and Member of Board of Trustees
Chairman and a Professor of the Department of Ophthalmology
Vice Provost for Academic Affairs and Deputy Chairman of Selection Committee
Dean of Freshmen and Transfer Students
Compensation as of Fiscal Year 2015.
Stanford University Key Developments
Medgenics Seals Exclusive Deal to License Gene Therapy Technologies from Stanford University
Jan 6 16
Medgenics (MDGN) announced signing of a license with Stanford University that gives it exclusive rights to certain breakthrough gene therapy technologies. Under the license Medgenics gets exclusive rights for the autologous ex vivo use of Stanford's GeneRide novel promoter-less gene therapy technology in combination with Medgenics' proprietary TARGT technology.
Stanford University Announces Consolidated Earnings Results for the Year Ended August 31, 2015
Dec 10 15
Stanford University announced consolidated earnings results for the year ended August 31, 2015. For the year, the company’s net assets increased $1.7 billion, or 5% at $35.5 billion. Operating revenues were $5.0 billion, up $453 million, or 10%, over the prior year.
Eiger BioPharmaceuticals Acquires License from Stanford University to Pulmonary Arterial Hypertension Program
Nov 11 15
Eiger BioPharmaceuticals has acquired an exclusive license to pulmonary arterial hypertension program from Stanford University in the US. The technology targets effects of leukotriene B4 for modulating inflammation and immune response in the lung, providing a potential therapeutic approach to treat PAH. Eiger committed to undertake a clinical study to assess if blocking the effects of LTB4 may be a useful new treatment for PAH.
Similar Private Companies By Industry
Recent Private Companies Transactions